WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Exit Postmarket & security

THE TAPE

Comments close on FDA's generative AI device framework Solventum clears its Restrata matrix for use under V.A.C. negative pressure therapy Medtronic takes a CE mark for five conduction system pacing pacemakers Paradromics hands Siemens Healthineers the imaging workup for its brain implant Empyrean submits a 510(k) for Vektra, its robotic brachytherapy system Masimo clears AFib detection on the Radius VSM wearable monitor Sequel clears the twiist insulin pump for adults with type 2 diabetes FTC issues a second request on the MiMedx purchase of Sanara MedTech Labcorp pays $722M upfront for BioReference testing assets Comments close on FDA's generative AI device framework Solventum clears its Restrata matrix for use under V.A.C. negative pressure therapy Medtronic takes a CE mark for five conduction system pacing pacemakers Paradromics hands Siemens Healthineers the imaging workup for its brain implant Empyrean submits a 510(k) for Vektra, its robotic brachytherapy system Masimo clears AFib detection on the Radius VSM wearable monitor Sequel clears the twiist insulin pump for adults with type 2 diabetes FTC issues a second request on the MiMedx purchase of Sanara MedTech Labcorp pays $722M upfront for BioReference testing assets

510(k)

Solventum clears its Restrata matrix for use under V.A.C. negative pressure therapy

MedDevice Startups Staff · 2 days ago · 2 min read · Via Solventum release

FDA cleared the combined use of Solventum's Restrata Synthetic Electrospun Fiber Matrix and the company's V.A.C. Therapy, Solventum said on October 19. The clearance names the V.A.C. Ulta Therapy Unit, the V.A.C. Peel and Place Dressing and Kit, and the V.A.C. Granufoam Dressing and Kit.

Restrata came to Solventum with Acera Surgical, which it bought in December 2025. The matrix is fully synthetic and resorbable, and it degrades by hydrolysis rather than enzymatically. V.A.C. Therapy applies negative pressure to the wound bed. Solventum says the Peel and Place dressing holds the matrix in close contact with the wound and can stay in place for up to seven days per application.

Solventum released no K number and no clinical outcome data with the announcement. Adding a combination claim to the labels of two products a company already sells is a routine submission, and it is usually what makes an acquired product sellable alongside an installed base of capital equipment.

Questions & Answers

What did Solventum get FDA clearance for in October 2026?

On October 19, 2026, Solventum announced FDA 510(k) clearance for the combined use of its Restrata Synthetic Electrospun Fiber Matrix and Solventum V.A.C. Therapy, its negative pressure wound therapy system.

Which V.A.C. Therapy products are named in the Solventum Restrata clearance?

The October 2026 clearance covers use of Restrata with the V.A.C. Ulta Therapy Unit, the V.A.C. Peel and Place Dressing and Kit, and the V.A.C. Granufoam Dressing and Kit. Solventum says the Peel and Place dressing can stay on for up to seven days per application.

Where did Solventum's Restrata matrix come from?

Restrata came from Acera Surgical, which Solventum acquired in December 2025. The October 19, 2026 clearance pairs that acquired matrix with Solventum's own V.A.C. Therapy platform.

← Back to Newly Cleared